Barclays PLC (BARC) — Investment Research Note

Executive summary

Barclays is a UK-centred diversified universal bank with consumer, corporate and wealth franchises in the UK, a top-tier global investment bank, and a specialist US cards business. The trajectory across the period covered shows steadily improving returns — from a 10.4% RoTE in 2022 through 13.2% in H125 — driven by structural hedge income, cost discipline, the Tesco Bank acquisition, and a strong rebound in Global Markets. The single most important point for valuation today: at 473p the shares trade at ~1.23x H125 tangible book of 384p, which already discounts management's >12% 2026 RoTE target, so further re-rating requires sustained execution against the £10bn 2024–26 capital return plan.

Fair value estimate

• Methodology: P/TNAV applied to a sustainable RoTE / cost-of-equity framework, cross-checked against forward P/E.
• Inputs: H125 TNAV 384p; sustainable RoTE 11–13% 2025-07 half-year; COE 10–11%; H125 annualised EPS run-rate ~49p.
• Bear (1.1x TNAV): 422p — assumes RoTE settles at ~11%, IB returns mean-revert lower.
• Base (1.25x TNAV): 480p — RoTE 12% sustained, capital return plan executes on schedule.
• Bull (1.4x TNAV): 538p — RoTE 13%+ as IB takes share and rates stay supportive.
• Fair value range: 420–520p per share (mid ~470p).
• Implied market cap range: £56,800m – £70,400m (current £63,961m).
• Absolute upside vs. 472.85p: roughly -11% to +10% (mid ~0%).

View: fair. The shares are essentially at midpoint of fair value after a +46% one-year run; the easy money on the rate-cycle/structural-hedge story has been made.

Sector context

• Sector confirmed: Financials / Banks (ICB).
• Quality / growth / leverage profile is in line with UK universal banking peers — better capital position than continental European banks (CET1 14.0%), comparable RoTE to large US banks but lower than the best-in-class, leverage profile typical of the industry.
• Listed peers: Lloyds Banking Group, NatWest, HSBC; for the IB the more direct comp is Deutsche Bank.

Investment thesis (3 bullets)

1. Structural hedge tailwind plus operating leverage from the three-year plan. The product/equity structural hedge stood at £232bn notional with gross contributions of £2.8bn in H125 (up from £2.2bn in H124), with a multi-year roll onto higher rates baked in. Combined with £2bn of gross cost efficiency savings targeted by 2026 and continued cost:income compression to "high 50s", incremental income should drop disproportionately to profit 2025-07 half-year.
2. Highly visible capital return. Management has committed to returning at least £10bn between 2024 and 2026 via dividends and buybacks (£1bn buyback announced with H125, total H125 distribution 3.0p + £1bn = c.10.1p/share equivalent). At current price this represents an attractive shareholder yield underpinned by a 14.0% CET1 ratio and ongoing organic generation 2025-07 half-year.
3. Investment Bank operating leverage to capital markets recovery. IB H125 RoTE 14.2%, income +13% YoY, with continued share gains in Global Markets and Equities. If the AI-driven M&A and IPO cycle accelerates — as evidenced by Barclays' role advising on transactions such as the Qualcomm/Alphawave deal — Banking fee income could surprise materially given the operating leverage of the platform 2025-07 half-year.

Key risks (3 bullets)

1. Legal/conduct overhang remains live. The motor finance commission review (FCA + Supreme Court awaiting judgment) and historic litigation (LIBOR, FX, ATS, US over-issuance of securities) create a long tail of provisions. Barclays has booked a £90m motor finance provision in 2024 but flags ultimate financial impact "could be materially different" 2025-07 half-year; 2022 saw a £966m hit from the Over-issuance of Securities.
2. Credit cycle / US cards normalisation. USCB LLR is already running at 523bps in H125 with 30-day arrears at 2.8% and an 11.6% total coverage ratio. A US recession or sharp consumer deterioration would meaningfully impact group impairment, with Barclays' own Downside 2 scenario projecting US unemployment to 7.8% 2025-07 half-year.
3. IB earnings volatility / regulatory capital uplift. IB Q225 income +10% YoY but is inherently cyclical; the bank also expects c.£16bn of additional RWAs from USCB moving to IRB during 2026 plus the Basel 3.1 implementation from January 2027, which constrains capital flexibility 2025-07 half-year.

Operating leverage

Barclays has meaningful operating leverage by virtue of its high fixed cost base (£8.4bn H125 operating costs against £14.9bn income; cost:income 58%). The structural hedge programme produces a multi-year tail of locked-in revenue with little marginal cost — every 100bps lift in the structural hedge yield translates directly into NII with negligible expense. Management explicitly targets c.£2bn of gross cost efficiency savings by 2026, of which ~£350m was delivered in H125; the cost:income trajectory from 67% in 2022 to "high 50s" in 2026 implies that on the targeted c.£30bn 2026 income, every 10% positive revenue surprise above plan could plausibly add ~50% to operating profit. The Investment Bank is the highest-leverage piece: Q225 IB profit before impairment +22% YoY on +10% income, with H125 IB cost:income improving to 56% from 61%. The big caveat is regulatory capital — operating leverage is constrained by RWA growth and the CET1 13–14% range, so upside is partially recycled into capital returns rather than profit growth 2025-07 half-year.

Value-trap signals

None identified at the franchise level. The recurring litigation/conduct charge stream (~£0.1–1.6bn per year) is a real but quantifiable drag, not a value-trap signal. Improving RoTE, growing capital returns, and a stable deposit franchise all point to a healthy business.

Earnings vs. expectations

The filings show management guidance set at full-year results and consistently upgraded or met through the year. The FY25 guidance was raised mid-year: Group NII ex-IB/Head Office target lifted from c.£10.7bn to c.£11.0bn and then to "greater than £12.5bn"; Barclays UK NII raised from c.£6.1bn to c.£6.3bn then to "greater than £7.6bn"; full-year RoTE target raised from ">10%" to "c.11%". H125 RoTE of 13.2% comfortably beat the c.11% target. The pattern across 2023–H125 is mostly beats and upward guidance revisions, with H124 also beating the original FY24 plan. Analyst consensus references are limited in the filings but management's own bar has been moved up repeatedly.

Conviction

Conviction: 4 — high. Anchored by (i) clean, well-disclosed financials with detailed quarterly segmental data; (ii) a simple and appropriate P/TNAV-on-sustainable-RoTE valuation framework that works well for diversified banks; (iii) a consistent execution track record over 6+ quarters against publicly disclosed targets. Limited by (i) IB earnings cyclicality which adds noise to the sustainable RoTE assumption; (ii) the unquantified motor finance and other legal contingencies which could shift the fair value range modestly.

Driver scoring

• ai_beneficiary (22): Barclays spends on AI internally — it is a buyer of AI tooling, not a recipient of AI buildout spend. Limited AI-receiver angle through Investment Bank advisory on AI deals (e.g. Qualcomm/Alphawave) but this is a small fraction of group income.
• operating_leverage (58): Meaningful operating leverage via structural hedge, cost programme and IB; but capital-constrained business model and rate sensitivity cap the upside.
• earnings_surprise_trend (68): H124, FY24, H125 all involved upward revisions to guidance and beats vs. original plan.
• cyclicality (62): Diversified universal bank — IB is highly cyclical, UK consumer and UKCB more stable, USCB sensitive to US consumer cycle.
• moat (55): Scale and regulatory moat in UK consumer/corporate banking; deposit franchise is a real asset; IB has top-tier non-US standing but commoditised in places.
• leverage (75): Banks are by nature highly leveraged entities; CET1 14.0% is strong for the sector but the gearing is intrinsic. Scoring on absolute balance sheet leverage as the rubric requests.
• earnings_quality (60): Generally clean accrual accounting and good cash conversion at group level, but recurring litigation/conduct charges and PMA-heavy IFRS9 provisioning warrant some caution.
• management_quality (62): Venkat has executed the three-year plan credibly to date; capital returns delivered on commitment; historic conduct issues (LIBOR, FX, ATS, Over-issuance of Securities) cap the score.
• growth_momentum (65): Mid-single-digit income growth, double-digit profit growth, RoTE accelerating; clear momentum but rate-cycle-dependent.

Overall score: 330

Overall score rationale: Solid diversified financial with improving returns, attractive capital return profile and reasonable valuation, but the AI-receiver angle is essentially absent (banks spend on AI; the value capture goes to their suppliers). Operating leverage is moderate, valuation is fair rather than cheap, and the upside is largely already priced after a 46% one-year rally. A good business but a poor fit for the strategy's three pillars.